Bolder BioTechnology, uses advanced protein engineering technologies to create proprietary, long-acting human protein pharmaceuticals for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. Now talk about achieving milestones…Bolder BioTechnology has been on a roll! Most recently BB was awarded a $685,984 Phase II SBIR grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH) to continue research towards optimizing a human protein to enhance its ability to inhibit formation of new blood vessels which may provide a novel approach for the treatment of rheumatoid arthritis. BB was also recently awarded a $762,475 Phase II SBIR grant from the National Institute of Allergy and Infectious Diseases (NIH) to continue study and improvement of the pharmacological properties of a human gamma interferon and to enhance its ability to stimulate the body's immune system to fight infections.
Tremendous achievements on the IP side as well! BB was granted patent 7,253,267 for their long-acting, second generation interleukin-11 analog product. IL-11 is a human protein that stimulates bone marrow cells to divide and differentiate into platelets which are important components of the blood clotting system. This product may prove useful as a chemotherapy co-treatment and for treating other diseases characterized by low platelet levels, such as myelodysplastic syndrome. BB was also recently granted patents 7,214,779 and 7,232,885 that broaden the scope of protection for their long-acting, second generation granulocyte-macrophage colony-stimulating factor (GM-CSF) analog and granulocyte colony-stimulating factor (G-CSF) analog programs. G-CSF and GM-CSF are human proteins that cause bone marrow cells to divide and differentiate into mature white blood cells.
Congratulations to President & CEO Joe Cox, Ph.D. on all of the fantastic progress!
If you enjoyed this post, get free updates by email (here)